Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders

References

• Barnes, T. R. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676. doi:10.1192/bjp.154.5.672
   PubMed Web of Science ®Google Scholar
• Barnes, T. R. (2003). The Barnes Akathisia Rating Scale–revisited. Journal of Psychopharmacology, 17(4), 365–370. doi:10.1177/0269881103174013
   PubMed Web of Science ®Google Scholar
• Callaghan, R. C., Cunningham, J. K., Sajeev, G., & Kish, S. J. (2010). Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders. Movement Disorders, 25(14), 2333–2339. doi:10.1002/mds.23263
   PubMed Web of Science ®Google Scholar
• Callaghan, R. C., Cunningham, J. K., Sykes, J., & Kish, S. J. (2012). Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug and Alcohol Dependence, 120(1–3), 35–40. doi:10.1016/j.drugalcdep.2011.06.013
   PubMed Web of Science ®Google Scholar
• Carey, K. B., & Correia, C. J. (1998). Severe mental illness and addictions: Assessment considerations. Addictive Behaviors, 23(6), 735–748. doi:10.1016/S0306-4603(98)00063-X
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Mathers, B., Guarinieri, M., Panda, S., Phillips, B., Strathdee, S. A., …. & Howard, J. (2010). Meth/amphetamine use and associated HIV: Implications for global policy and public health. International Journal of Drug Policy, 21(5), 347–358. doi:10.1016/j.drugpo.2009.11.007
   PubMed Web of Science ®Google Scholar
• First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1994). Structured Clinical Interview for DSM-IV Axis I disorders-Patient Edition (SCID-I-P, version 2). Biometrics Research Department, New York Psychiatric Institute, 722 West 168th Street, New York, New York 10032.
   Google Scholar
• Fleckenstein, A. E., Gibb, J. W., & Hanson, G. R. (2000). Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity. European Journal of Pharmacology, 406(1), 1–13. doi:10.1016/S0014-2999(00)00639-7
   PubMed Web of Science ®Google Scholar
• Gardner, D. M., Murphy, A. L., O’Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010). International consensus study of antipsychotic dosing. American Journal of Psychiatry, 167(6), 686–693. doi:10.1176/appi.ajp.2009.09060802
   PubMed Web of Science ®Google Scholar
• Guy, W. (1976). ECDEU assessment manual for psychopharmacology-revised (DHHS Publ No ADM 91-338) (pp. 534–537). Rockville, MD: US Department of Health and Human Services.
   Google Scholar
• Howells, F. M., Temmingh, H. S., Hsieh, J. H., van Dijen, A. V., Baldwin, D. S., & Stein, D. J. (2018). Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: A study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder. Translational Psychiatry, 8(1), 75. doi:10.1038/s41398-018-0105-y
   PubMedGoogle Scholar
• Jan, R. K., Kydd, R. R., & Russell, B. R. (2012). Functional and structural brain changes associated with methamphetamine abuse. Brain Sciences, 2(4), 434–482. doi:10.3390/brainsci2040434
   PubMedGoogle Scholar
• Keck, P. E., Jr., McElroy, S. L., Strakowski, S. M., & Soutullo, C. A. (2000). Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Journal of Clinical Psychiatry, 61 (Suppl 4), 33–38. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10739329
   PubMed Web of Science ®Google Scholar
• Lambert, M., Conus, P., Lubman, D. I., Wade, D., Yuen, H., Moritz, S., … Schimmelmann, B. G. (2005). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica. 112(2), 141–148. doi:10.1111/j.1600-0447.2005.00554.x
   PubMed Web of Science ®Google Scholar
• Leucht, S., Heres, S., Hamann, J., & Kane, J. M. (2008). Methodological issues in current antipsychotic drug trials. Schizophrenia Bulletin, 34(2), 275–285. doi:10.1093/schbul/sbm159
   PubMed Web of Science ®Google Scholar
• Leucht, S., Samara, M., Heres, S., & Davis, J. M. (2016). Dose equivalents for antipsychotic drugs: The DDD method. Schizophrenia Bulletin, 42(Suppl. 1), S90–S94. doi:10.1093/schbul/sbv167
   PubMedGoogle Scholar
• Maat, A., Fouwels, A., & de Haan, L. (2008). Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacology Bulletin, 41(3), 5–10. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18779773
   PubMedGoogle Scholar
• Matthew, B. J., & Gedzior, J. S. (2015). Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate. International Journal of Psychiatry in Medicine, 50(4), 405–411. doi:10.1177/0091217415612736
   PubMed Web of Science ®Google Scholar
• Miller, D. D., McEvoy, J. P., Davis, S. M., Caroff, S. N., Saltz, B. L., Chakos, M. H., … Lieberman, J. A. (2005). Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophrenia Research, 80(1), 33–43. doi:10.1016/j.schres.2005.07.034
   PubMed Web of Science ®Google Scholar
• Moszczynska, A., Fitzmaurice, P., Ang, L., Kalasinsky, K. S., Schmunk, G. A., Peretti, F. J., … Kish, S. J. (2004). Why is parkinsonism not a feature of human methamphetamine users? Brain, 127(2), 363–370. doi:10.1093/brain/awh046
   PubMedGoogle Scholar
• Nutt, D. J., Lingford-Hughes, A., Erritzoe, D., & Stokes, P. R. (2015). The dopamine theory of addiction: 40 years of highs and lows. Nature Reviews Neuroscience, 16(5), 305–312. doi:10.1038/nrn3939
   PubMed Web of Science ®Google Scholar
• Patel, M. X., Arista, I. A., Taylor, M., & Barnes, T. R. (2013). How to compare doses of different antipsychotics: A systematic review of methods. Schizophrenia Research, 149(1–3), 141–148. doi:10.1016/j.schres.2013.06.030
   PubMed Web of Science ®Google Scholar
• Patterson-Lomba, O., Ayyagari, R., & Carroll, B. (2019). Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: A retrospective data analysis. BMC Neurology, 19(1), 174. doi:10.1186/s12883-019-1385-4
   PubMedGoogle Scholar
• Peluso, M. J., Lewis, S. W., Barnes, T. R., & Jones, P. B. (2012). Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. British Journal of Psychiatry, 200(5), 387–392. doi:10.1192/bjp.bp.111.101485
   PubMed Web of Science ®Google Scholar
• Pluddemann, A., Dada, S., Parry, C. D., Kader, R., Parker, J. S., Temmingh, H., … Lewis, I. (2013). Monitoring the prevalence of methamphetamine-related presentations at psychiatric hospitals in Cape Town, South Africa. African Journal of Psychiatry, 16(1), 45–49. doi:10.4314/ajpsy.v16i1.8
   Google Scholar
• Potvin, S., Blanchet, P., & Stip, E. (2009). Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis. Schizophrenia Research, 113(2–3), 181–188. doi:10.1016/j.schres.2009.06.010
   PubMed Web of Science ®Google Scholar
• Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., & Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association, 264(19), 2511–2518. doi:10.1001/jama.1990.03450190043026
   PubMed Web of Science ®Google Scholar
• Richardson, M. A., Pass, R., Bregman, Z., & Craig, T. J. (1985). Tardive dyskinesia and depressive symptoms in schizophrenics. Psychopharmacology Bulletin, 21(1), 130–135. Retrieved from https://europepmc.org/article/med/2858905
   PubMedGoogle Scholar
• Rumpf, J. J., Albers, J., Fricke, C., Mueller, W., & Classen, J. (2017). Structural abnormality of substantia nigra induced by methamphetamine abuse. Movement Disorders, 32(12), 1784–1788. doi:10.1002/mds.27205
   PubMed Web of Science ®Google Scholar
• Schooler, N. R., & Kane, J. M. (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry, 39(4), 486–487. doi:10.1001/archpsyc.1982.04290040080014
   PubMed Web of Science ®Google Scholar
• Seeman, P. (2002). Atypical antipsychotics: Mechanism of action. Canadian Journal of Psychiatry, 47(1), 29–40. doi:10.1177/070674370204700106
   Web of Science ®Google Scholar
• Shelly, J., Uhlmann, A., Sinclair, H., Howells, F. M., Sibeko, G., Wilson, D., … Temmingh, H. (2016). First-Rank symptoms in methamphetamine psychosis and schizophrenia. Psychopathology, 49(6), 429–435. doi:10.1159/000452476
   PubMed Web of Science ®Google Scholar
• Sibeko, G., Temmingh, H., Mall, S., Williams-Ashman, P., Thornicroft, G., Susser, E. S., … Milligan, P. D. (2017). Improving adherence in mental health service users with severe mental illness in South Africa: A pilot randomized controlled trial of a treatment partner and text message intervention vs. treatment as usual. BMC Research Notes, 10(1), 584. doi:10.1186/s13104-017-2915-z
   PubMedGoogle Scholar
• Simpson, G. M., & Angus, J. W. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 45(Suppl. 212), 11–19. doi:10.1111/j.1600-0447.1970.tb02066.x
   Google Scholar
• StataCorp. (2013). Stata statistical software: Release 13. College Station, TX: StataCorp LP.
   Google Scholar
• Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Ding, Y. S., Sedler, M., … Pappas, N. (2001). Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. American Journal of Psychiatry, 158(12), 2015–2021. doi:10.1176/appi.ajp.158.12.2015
   PubMed Web of Science ®Google Scholar
• Wobrock, T., Falkai, P., Schneider-Axmann, T., Hasan, A., Galderisi, S., Davidson, M., … Fleischhacker, W. W. (2013). Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. Schizophrenia Research, 147(1), 132–139. doi:10.1016/j.schres.2013.03.001
   PubMed Web of Science ®Google Scholar
• Zhornitsky, S., Stip, E., Pampoulova, T., Rizkallah, E., Lipp, O., Bentaleb, L. A., … Potvin, S. (2010). Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disorders, 25(13), 2188–2194. doi:10.1002/mds.23227
   PubMed Web of Science ®Google Scholar